Cost-Utility of an Online Education Platform and Diabetes Personal Health Record: Analysis Over Ten Years
Authors' conclusion
MDMW is "dominant" over usual care (cost-saving and life improving) in supporting self-management in people with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or reduction of long-term complications and improved QALYs in Scotland and other countries. MDMW may be among the most cost-effective interventions currently available to support diabetes.
Study context
- Population
- People with T2D not using insulin, Scotlandmatched cohort
- Participants
- 2,576 vs 11,628
- Exposure
- My Diabetes My Way (MDMW) vs routine diabetes care
- MDMWn = 2,576
- Routine caren = 11,628reference
- Outcome
- Quality-adjusted life years (QALYs) and costs (UKPDS Outcomes Model 2 simulation)
- Follow-up
- 10 years
Methodological detailsUnited Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model 2 simulation, matched cohort, 10-year horizon, 10% sensitivity analysis
- UKPDS Outcomes Model 2 simulation
- Matched cohort
- 10-year horizon
- 10% sensitivity analysis
Main finding
As reported in the abstract
Cumulative mean QALY gain
0.054 (0.044-0.062) years (95% CI)
Mean difference in cost over ten years
-£118.72
-£150.16 to -£54.16
Observational data: associations, not effects.
Further findings
| Outcome | Mean difference in cost (CI) |
|---|---|
| Sensitivity analysis: mean difference in cost with MDMW costs increased 10% · ten years | -£50.49 (-£82.24-£14.14) |
| Sensitivity analysis: mean difference in cost with MDMW costs decreased 10% · ten years | -£186.95 (-£218.53 to -£122.51) |
MDMW cohort characteristics
- Men
- 1670 (64.8%); average age 64.3 years; diabetes duration 5.5 years
- Women
- 906 (35.2%); average age 61.6 years; duration 4.7 years
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →